Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477087 · ClinicalTrials.gov registry record · Phase 2
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00477087: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00477087 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477087, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.
Interventions
- DRUG Mitoxantrone
- DRUG GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477087
The ClinicalTrials.gov registry entry for NCT00477087 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mitoxantrone is the first listed.
NCT00477087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477087 about?
NCT00477087 is a clinical study titled "Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer". The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.
What is the current status of trial NCT00477087?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-07. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00477087?
The interventions under investigation include: Mitoxantrone (DRUG), GM-CSF (DRUG).
Who is sponsoring clinical trial NCT00477087?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.